Non Hodgkin Lymphoma (NHL) Global Market Report 2025

Description

Non-Hodgkin lymphoma (NHL) is a cancer impacting the lymphatic system, characterized by abnormal white blood cell growth within the body's immune system, which typically fights infections.

The main types of NHL include B-cell lymphoma and T-cell lymphoma. B-cell lymphoma involves abnormal B lymphocytes in the immune system. Treatment for B-cell lymphomas often encompasses a combination of therapies such as chemotherapy, immunotherapy, targeted therapy, radiation therapy, and potentially stem cell transplants. Various treatment modalities including surgery, stem cell transplants, chemotherapy, immunotherapy, targeted therapy, and radiation therapy can be administered through different routes such as oral or parenteral methods. These treatments are available through diverse distribution channels including hospital pharmacies, retail outlets, online pharmacies, and others. They are utilized by various end-users including hospitals, homecare facilities, specialty centers, and other medical settings.

The non Hodgkin lymphoma market research report is one of a series of new reports from The Business Research Company that provides non Hodgkin lymphoma market statistics, including non Hodgkin lymphoma industry global market size, regional shares, competitors with a non Hodgkin lymphoma market share, detailed non Hodgkin lymphoma market segments, market trends and opportunities, and any further data you may need to thrive in the non Hodgkin lymphoma industry. This non Hodgkin lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non hodgkin lymphoma (NHL) market size has grown strongly in recent years. It will grow from$10.11 billion in 2024 to $11.01 billion in 2025 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to increased incidence of NHL, advancements in diagnostics, chemotherapy and immunotherapy, clinical research and drug development, improved survival rates

The non hodgkin lymphoma (NHL) market size is expected to see strong growth in the next few years. It will grow to $15.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to growing aging population, advancements in targeted therapies, immunotherapy innovations, precision medicine approaches, increasing awareness and early detection. Major trends in the forecast period include rise of biosimilars, integration of next-generation sequencing, adoption of car-t cell therapies, novel chemotherapy agents, real-world evidence and outcomes research.

The anticipated surge in the non-Hodgkin lymphoma market is primarily fueled by the condition's widespread prevalence. Non-Hodgkin lymphoma, a cancer originating in the lymphatic system, is becoming increasingly common among populations. As highlighted by the American Cancer Society's January 2023 report, it constitutes 4% of all cancers and is projected to affect approximately 80,550 Americans in 2023, leading to an estimated 20,180 fatalities. Similarly, data from the Canadian Cancer Society in May 2022 indicated 11,400 diagnosed cases of non-Hodgkin lymphoma in Canada that year, resulting in 3,000 fatalities. This escalating prevalence underscores the driving force behind the non-Hodgkin lymphoma market's growth.

The burgeoning elderly population is poised to be a key driver for the expansion of the non-Hodgkin lymphoma (NHL) market. With a higher incidence of this ailment among older adults, the specialized care and treatment required for this segment emphasize the market's trajectory. As forecasted by the World Health Organization in October 2022, the global elderly population, defined as individuals aged 65 and above, is set to reach 2.1 billion by 2050, making up one-sixth of the world's populace by 2030. Consequently, the rising demographic of elderly individuals contributes significantly to the expansion of the non-Hodgkin lymphoma (NHL) market.

The non-Hodgkin lymphoma market is witnessing a significant trend in drug innovation, driving advancements in treatment options. Companies operating in this sector are actively pursuing product innovation to fortify their market positions. Genentech Inc.'s December 2022 FDA approval for Lunsumio, a novel bispecific antibody targeting relapsed or refractory follicular lymphoma, exemplifies this trend. This immunotherapy, a fixed-duration cancer treatment, provides readily available options for patients without delays in receiving treatment, based on positive outcomes from Phase II GO29781 research.

Major players in the non-Hodgkin lymphoma market are intensifying their focus on introducing cutting-edge immunotherapies such as Epcoritamab-bysp (EPKINLY) to gain a competitive edge. This investigational subcutaneous immunotherapy, targeting CD20-expressing B-cell malignancies, has exhibited promising results in clinical trials, notably in relapsed or refractory B-cell non-Hodgkin lymphoma. AbbVie Inc.'s November 2023 breakthrough therapy designation from the FDA for Epcoritamab-bysp (EPKINLY) in treating adult patients with relapsed or refractory follicular lymphoma marks a significant milestone. Additionally, the EMA's validation of a Type II application for epcoritamab (TEPKINLY) for the same indication is supported by encouraging results from the Phase 1/2 EPCORE NHL-1 clinical trial, involving 128 adult patients with relapsed or refractory CD20+ mature B-cell non-Hodgkin's lymphoma (NHL), including FL.

In August 2022, AstraZeneca plc, a prominent UK-based pharmaceutical and biotechnology entity, completed the undisclosed acquisition of TeneoTwo Inc. This strategic move aims to significantly enhance and diversify AstraZeneca's product lineup by incorporating oncology medications and a pipeline featuring TNB-486, a phase I clinical-stage CD19/CD3 T-cell engager specifically tailored for addressing relapsed and refractory B-cell non-Hodgkin lymphoma. TeneoTwo Inc., based in the US, specializes in biotechnological advancements within oncology, notably in the realm of treatments for NHL.

Major companies operating in the non hodgkin lymphoma (NHL) market include Bayer AG, Teva Pharmaceutical Industries Ltd., F. Hoffmann La Roche Ltd., Merck & Co. Inc., Eli Lilly and Co., Novartis AG, GlaxoSmithKline plc, AbbVie Inc., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Co., Pfizer Inc., Celgene Corporation, Sanofi S.A., Janssen Pharmaceuticals Inc., Johnson & Johnson, Biogen Idec, Boehringer Ingelheim GmbH, Eisai Co. Ltd., Gilead Sciences, Incyte Corporation, Karyopharm Therapeutics, Kite Pharma Inc., Kyowa Hakko Kirin Co. Ltd., MorphoSys AG, Nordic Nanovector ASA, Ono Pharmaceutical Co. Ltd., Seattle Genetics Inc., Spectrum Pharmaceuticals Inc.

North America was the largest region in the non-Hodgkin lymphoma (NHL) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global non-Hodgkin lymphoma (NHL) market report during the forecast period. The regions covered in the non hodgkin lymphoma (nhl) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the non hodgkin lymphoma (nhl) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The non-Hodgkin lymphoma market includes revenues earned by entities by treating aggressive lymphomas, indolent lymphomas, Burkitt lymphoma, lymphoma and leukemia, and B-cell lymphomas. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non Hodgkin Lymphoma (NHL) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non hodgkin lymphoma (nhl) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non hodgkin lymphoma (nhl) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non hodgkin lymphoma (nhl) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: B-Cell Lymphoma; T-Cell Lymphoma
2) By Treatment: Surgery; Stem Cell Transplant; Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy
3) By Route of Administration: Oral; Parenteral; Other Routes of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
5) By End-Users: Hospitals; Homecare; Specialty Centers; Other End Users
Subsegments:
1) By B-Cell Lymphoma: Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma; Chronic Lymphocytic Leukemia (CLL); Mantle Cell Lymphoma; Burkitt Lymphoma; Marginal Zone Lymphoma; Primary Mediastinal B-Cell Lymphoma
2) By T-Cell Lymphoma: Peripheral T-Cell Lymphoma (PTCL); Anaplastic Large Cell Lymphoma (ALCL); Cutaneous T-Cell Lymphoma (CTCL); T-Cell Lymphoblastic Lymphoma; Adult T-Cell Leukemia/Lymphoma (ATLL)
Companies Mentioned: Bayer AG; Teva Pharmaceutical Industries Ltd.; F. Hoffmann La Roche Ltd.; Merck & Co. Inc.; Eli Lilly and Co.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r24366

1. Executive Summary

2. Non Hodgkin Lymphoma (NHL) Market Characteristics

3. Non Hodgkin Lymphoma (NHL) Market Trends And Strategies

4. Non Hodgkin Lymphoma (NHL) Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Non Hodgkin Lymphoma (NHL) Growth Analysis And Strategic Analysis Framework

5.1. Global Non Hodgkin Lymphoma (NHL) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Non Hodgkin Lymphoma (NHL) Market Growth Rate Analysis
5.4. Global Non Hodgkin Lymphoma (NHL) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Non Hodgkin Lymphoma (NHL) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Non Hodgkin Lymphoma (NHL) Total Addressable Market (TAM)

6. Non Hodgkin Lymphoma (NHL) Market Segmentation

6.1. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
B-Cell Lymphoma
T-Cell Lymphoma
6.2. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgery
Stem Cell Transplant
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
6.3. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
Other Routes of Administration
6.4. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Other Distribution Channels
6.5. Global Non Hodgkin Lymphoma (NHL) Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Centers
Other End Users
6.6. Global Non Hodgkin Lymphoma (NHL) Market, Sub-Segmentation Of B-Cell Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Diffuse Large B-Cell Lymphoma (DLBCL)
Follicular Lymphoma
Chronic Lymphocytic Leukemia (CLL)
Mantle Cell Lymphoma
Burkitt Lymphoma
Marginal Zone Lymphoma
Primary Mediastinal B-Cell Lymphoma
6.7. Global Non Hodgkin Lymphoma (NHL) Market, Sub-Segmentation Of T-Cell Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peripheral T-Cell Lymphoma (PTCL)
Anaplastic Large Cell Lymphoma (ALCL)
Cutaneous T-Cell Lymphoma (CTCL)
T-Cell Lymphoblastic Lymphoma
Adult T-Cell Leukemia/Lymphoma (ATLL)

7. Non Hodgkin Lymphoma (NHL) Market Regional And Country Analysis

7.1. Global Non Hodgkin Lymphoma (NHL) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Non Hodgkin Lymphoma (NHL) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market

8.1. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non Hodgkin Lymphoma (NHL) Market

9.1. China Non Hodgkin Lymphoma (NHL) Market Overview
9.2. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non Hodgkin Lymphoma (NHL) Market

10.1. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non Hodgkin Lymphoma (NHL) Market

11.1. Japan Non Hodgkin Lymphoma (NHL) Market Overview
11.2. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non Hodgkin Lymphoma (NHL) Market

12.1. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non Hodgkin Lymphoma (NHL) Market

13.1. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non Hodgkin Lymphoma (NHL) Market

14.1. South Korea Non Hodgkin Lymphoma (NHL) Market Overview
14.2. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non Hodgkin Lymphoma (NHL) Market

15.1. Western Europe Non Hodgkin Lymphoma (NHL) Market Overview
15.2. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non Hodgkin Lymphoma (NHL) Market

16.1. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non Hodgkin Lymphoma (NHL) Market

17.1. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non Hodgkin Lymphoma (NHL) Market

18.1. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non Hodgkin Lymphoma (NHL) Market

19.1. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non Hodgkin Lymphoma (NHL) Market

20.1. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non Hodgkin Lymphoma (NHL) Market

21.1. Eastern Europe Non Hodgkin Lymphoma (NHL) Market Overview
21.2. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non Hodgkin Lymphoma (NHL) Market

22.1. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non Hodgkin Lymphoma (NHL) Market

23.1. North America Non Hodgkin Lymphoma (NHL) Market Overview
23.2. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non Hodgkin Lymphoma (NHL) Market

24.1. USA Non Hodgkin Lymphoma (NHL) Market Overview
24.2. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non Hodgkin Lymphoma (NHL) Market

25.1. Canada Non Hodgkin Lymphoma (NHL) Market Overview
25.2. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non Hodgkin Lymphoma (NHL) Market

26.1. South America Non Hodgkin Lymphoma (NHL) Market Overview
26.2. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non Hodgkin Lymphoma (NHL) Market

27.1. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non Hodgkin Lymphoma (NHL) Market

28.1. Middle East Non Hodgkin Lymphoma (NHL) Market Overview
28.2. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non Hodgkin Lymphoma (NHL) Market

29.1. Africa Non Hodgkin Lymphoma (NHL) Market Overview
29.2. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Non Hodgkin Lymphoma (NHL) Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non Hodgkin Lymphoma (NHL) Market Competitive Landscape And Company Profiles

30.1. Non Hodgkin Lymphoma (NHL) Market Competitive Landscape
30.2. Non Hodgkin Lymphoma (NHL) Market Company Profiles
- 30.2.1. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Eli Lilly and Co. Overview, Products and Services, Strategy and Financial Analysis

31. Non Hodgkin Lymphoma (NHL) Market Other Major And Innovative Companies

31.1. Novartis AG
31.2. GlaxoSmithKline plc
31.3. AbbVie Inc.
31.4. AstraZeneca plc
31.5. Takeda Pharmaceutical Company Limited
31.6. Bristol Myers Squibb Co.
31.7. Pfizer Inc.
31.8. Celgene Corporation
31.9. Sanofi S.A.
31.10. Janssen Pharmaceuticals Inc.
31.11. Johnson & Johnson
31.12. Biogen Idec
31.13. Boehringer Ingelheim GmbH
31.14. Eisai Co. Ltd.
31.15. Gilead Sciences

32. Global Non Hodgkin Lymphoma (NHL) Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non Hodgkin Lymphoma (NHL) Market

34. Recent Developments In The Non Hodgkin Lymphoma (NHL) Market

35. Non Hodgkin Lymphoma (NHL) Market High Potential Countries, Segments and Strategies

35.1 Non Hodgkin Lymphoma (NHL) Market In 2029 - Countries Offering Most New Opportunities
35.2 Non Hodgkin Lymphoma (NHL) Market In 2029 - Segments Offering Most New Opportunities
35.3 Non Hodgkin Lymphoma (NHL) Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer